MDM2 interacts with MDMX through their RING finger domains

The N‐terminus of MDM2 proto‐oncoprotein interacts with p53 and down modulates p53 activity by inhibiting transcriptional activity and promoting p53 degradation. MDMX is structurally related to MDM2 and also binds to p53. However, the function of MDMX has not been clarified yet. We found that MDM2 hetero‐oligomerized with MDMX through their C‐terminal RING finger domains. Yeast two‐hybrid analysis revealed that the hetero‐oligomerization between MDMX and MDM2 was more stable than the homo‐oligomerization of each protein. MDM2 has been shown to be degraded by the ubiquitin‐proteasome pathway, while MDMX was a stable protein. Interaction of MDMX with MDM2 through the C‐terminal RING finger domains resulted in inhibiting degradation of MDM2. These data indicate that MDMX functions as a regulator of MDM2.

• Publication year

  1999

• Venue

  FEBS Letters

• Publication date

  1999-03-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-5793(99)00254-9PMID 10218570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

  1999cited by this paper
• The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2

  1998cited by this paper
• BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

  1998cited by this paper
• p53-independent role of MDM2 in TGF-beta1 resistance.

  1998cited by this paper
• p53-Independent Role of MDM2 in TGF-β1 Resistance

  1998cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998cited by this paper
• mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.

  1998cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation

  1997cited by this paper
• Isolation and identification of the human homolog of a new p53-binding protein, Mdmx.

  1997cited by this paper
• Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases*

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis*

  1997cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• p53 in growth control and neoplasia.

  1996cited by this paper
• MDMX: a novel p53‐binding protein with some functional properties of MDM2.

  1996cited by this paper
• Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer

  1996cited by this paper
• Identification of a RING protein that can interact in vivo with the BRCA1 gene product

  1996cited by this paper
• p53: puzzle and paradigm.

  1996cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper
• Mapping of the p53 and mdm-2 interaction domains.

  1993cited by this paper
• Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

  1993cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

  1987cited by this paper

• Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells

  2025cites this paper
• A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.

  2025cites this paper
• Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

  2025influential citation
• Exploring the heterodimer MDM2/MDM4 interaction region uncovers high-affinity peptides for therapeutic p53-reactivation

  2025cites this paper
• Structure and function of MDM2 and MDM4 in health and disease

  2025cites this paper
• Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.

  2024cites this paper
• A defective splicing machinery promotes senescence through MDM4 alternative splicing

  2024cites this paper
• Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus.

  2024cites this paper
• An Anti-Invasive Role for Mdmx through the RhoA GTPase under the Control of the NEDD8 Pathway

  2024cites this paper
• The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress

  2024cites this paper
• Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

  2023cites this paper
• Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma.

  2023cites this paper
• TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2

  2023cites this paper
• The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.

  2022cites this paper
• Therapeutic Strategies to Activate p53

  2022cites this paper
• Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism

  2022cites this paper
• MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity

  2022cites this paper
• Alterations of the MDM2 C-terminus differentially impact its function in vivo.

  2022cites this paper
• MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53

  2021cites this paper
• MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail

  2021cites this paper
• The p53-p21 axis plays a central role in lymphatic homeostasis and disease

  2021cites this paper
• MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53

  2021cites this paper
• The role of miRNAs in MDMX‐p53 interplay

  2021cites this paper
• Studying Homo-oligomerization and Hetero-oligomerization of MDMX and MDM2 Proteins in Single Living Cells by Using In Situ Fluorescence Correlation Spectroscopy.

  2021cites this paper
• The ion channel TRPM7 regulates zinc-depletion-induced MDMX degradation

  2021cites this paper
• Bioflavonoid Hinokiflavone is a novel MDM2 inhibitor

  2021cites this paper
• Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells—Relevance for Understanding (Germ Cell) Tumorigenesis

  2021cites this paper
• Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

  2021cites this paper
• Association of MDM4 Gene rs4245739 Polymorphism with the Risk and Clinical Characteristics of Colorectal Cancer in a Chinese Han Population

  2020cites this paper
• p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo

  2020cites this paper
• Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

  2020cites this paper
• CMAR_A_260943 7715..7724

  2020cites this paper
• Mdm4 controls ureteric bud branching via regulation of p53 activity.

  2020cites this paper
• Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges

  2020cites this paper
• PDLIM7 Synergizes With PDLIM2 and p62/Sqstm1 to Inhibit Inflammatory Signaling by Promoting Degradation of the p65 Subunit of NF-κB

  2020cites this paper
• MDM2-C Functions as an E3 Ubiquitin Ligase

  2020cites this paper
• The Janus Face of p53-Targeting Ubiquitin Ligases

  2020cites this paper
• Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer

  2020cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• The long and the short of it: the MDM4 tail so far

  2019cites this paper
• Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells

  2019cites this paper
• A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize

  2019cites this paper
• Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx

  2018cites this paper
• The regulation of cellular signalling by the 5S RNP

  2018cites this paper
• p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction

  2018cites this paper
• The RING domain of RING Finger 11 (RNF11) protein binds Ubc13 and inhibits formation of polyubiquitin chains

  2018cites this paper
• The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy

  2018cites this paper
• Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

  2018cites this paper
• Generation of reporter cell lines by genome editing to probe p53 activity

  2018cites this paper
• Interferon‐stimulated gene 15 enters posttranslational modifications of p53

  2018cites this paper
• Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function

  2018cites this paper
• MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4

  2017cites this paper
• Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice

  2017cites this paper
• Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4

  2017cites this paper
• MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

  2017cites this paper
• In Vivo Discoveries in MDM2-Mediated p53 Regulation

  2017cites this paper
• EVALUATING THE THERAPEUTIC EFFICACY OF RESTORING WILD-TYPE P53 ACTIVITY IN P53-MUTANT TUMORS

  2017cites this paper
• p53 stability is regulated by diverse deubiquitinating enzymes.

  2017cites this paper
• Negative auto-regulators trap p53 in their web.

  2017cites this paper
• Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library

  2017cites this paper
• Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen

  2017influential citation
• p53: Multiple Facets of a Rubik's Cube.

  2017cites this paper
• Mdm proteins: critical regulators of embryogenesis and homoeostasis

  2017cites this paper
• MKRN2 is a novel ubiquitin E3 ligase for the p65 subunit of NF-κB and negatively regulates inflammatory responses

  2017cites this paper
• Evolution of the p53-MDM2 pathway

  2017cites this paper
• Mouse modelling of the MDM2/MDMX−p53 signalling axis

  2017influential citation
• Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network

  2017cites this paper
• The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2)

  2017cites this paper
• The MDMX (MDM4) oncoprotein as a therapeutic target and determinant of response to MDM2-p53 binding antagonists in human cancer

  2017cites this paper
• Alterations in Gene Expression and Sensitivity to Genotoxic Stress Following HdmX or Hdm2 Knockdown in Human Tumor Cells Harboring Wild-Type p53

  2017cites this paper
• The Role of MDM2 Phosphorylation in P53 Responses to DNA Damage and Tumor Suppression: A Dissertation

  2016influential citation
• A regulatory network of Mdm2 and members of the Polycomb Group (PcG) family

  2016cites this paper
• Mdm 2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis

  2016cites this paper
• Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions

  2016influential citation
• Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

  2016cites this paper
• Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

  2016influential citation
• Modulation of p53 signalling and response to MDM2-p53 binding antagonists

  2016cites this paper
• Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria

  2016cites this paper
• Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

  2016cites this paper
• Regulation of the p53 Pathway

  2016cites this paper
• Role of hnRNP A1 in the Regulation of HDM2 Gene Expression

  2016cites this paper
• MDM2–MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance

  2016cites this paper
• How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures

  2016cites this paper
• Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer

  2016cites this paper
• Intra molecular interactions in the regulation of p53 pathway.

  2016cites this paper
• Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis.

  2016cites this paper
• Characterisation of N-terminal fragments of Retinoblastoma Binding Protein 6 for structural analysis

  2016cites this paper
• Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB

  2016cites this paper
• Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.

  2016cites this paper
• Study of the Ribosomal Stress Pathway in Pluripotency, Cancer and Disease

  2016cites this paper
• MDM2 oligomers: antagonizers of the guardian of the genome

  2016cites this paper
• The Roles of MDM2 and MDMX in Cancer.

  2016cites this paper
• Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.

  2015cites this paper
• Exploring Chromatin-bound MDM2 Functions in Compromised Transcriptional Regulation of p53 Target Genes

  2015cites this paper
• IN VIVO SIGNIFICANCE OF THE MDM4 AND P73 INTERACTION DURING DEVELOPMENT AND TUMORIGENESIS

  2015cites this paper
• MDMX exerts its oncogenic activity via suppression of retinoblastoma protein

  2015cites this paper
• Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer

  2015cites this paper
• Novel functions of USP36 : regulation of histone 2B and the P53-MDM2 pathway through deubiquitination

  2015cites this paper
• Regulation and Function of p53 in Embryonic Stem Cells

  2015cites this paper
• Regulation of MDM2 Stability After DNA Damage

  2015influential citation